Fig. 3.
Fig. 3. Arachidonate metabolites in endothelial cell migration. / The migration assays were performed as described in “Materials and methods.” (A) Stimulation of RV-ECT migration by arachidonic acid (1 μmol/L), bFGF (10 ng/ml), and VEGF (10 ng/ml). (B) VEGF-stimulated RV-ECT migration involves lipoxygenase-dependent arachidonic acid metabolism. Treatment: VEGF, 10 ng/mL; ETYA, 5 μmol/L; NDGA, 50 μmol/L; indomethacin, 50 μmol/L. −, absence of treatment (vehicle only); +, presence of treatment. (C) Differential effects on RV-ECT cell migration by various HETEs. (D) Modulation of RV-ECT cell migration by 12-LOX inhibitor BHPP and 12(S)-HETE. Columns, percentage of the average number of cells migrated when compared with the controls; bars, SE (a, P < .05; b, P < 0.01; Student's t test). All migration assays were repeated at least 4 times.

Arachidonate metabolites in endothelial cell migration.

The migration assays were performed as described in “Materials and methods.” (A) Stimulation of RV-ECT migration by arachidonic acid (1 μmol/L), bFGF (10 ng/ml), and VEGF (10 ng/ml). (B) VEGF-stimulated RV-ECT migration involves lipoxygenase-dependent arachidonic acid metabolism. Treatment: VEGF, 10 ng/mL; ETYA, 5 μmol/L; NDGA, 50 μmol/L; indomethacin, 50 μmol/L. −, absence of treatment (vehicle only); +, presence of treatment. (C) Differential effects on RV-ECT cell migration by various HETEs. (D) Modulation of RV-ECT cell migration by 12-LOX inhibitor BHPP and 12(S)-HETE. Columns, percentage of the average number of cells migrated when compared with the controls; bars, SE (a, P < .05; b, P < 0.01; Student's t test). All migration assays were repeated at least 4 times.

Close Modal

or Create an Account

Close Modal
Close Modal